Genmab A/S (OTC:GNMSF)
Q2 2014 Earnings Conference Call
August 13, 2014 12:00 PM ET
Jan G. J. van de Winkel – President and Chief Executive Officer
David A. Eatwell – Executive Vice President & Chief Financial...
LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Denmark-based
biotechnology company Genmab A/S (GMXAY.PK, GNMSF.PK) announced that the
European Commission or EC has granted marketing authorization for a new
indication for the use of...
Welcome to the latest edition of our weekly EuroBiotech Report. With the battle for investor support in the AbbVie-Shire takeover tug of war heating up, the Ireland-headquartered biopharma has played up its European roots and rare position in the...
LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Genmab A/S said
Thursday that the U.S. Food and Drug Administration has approved a Supplemental
Biologic License Application for the use of Arzerra, a CD20-directed monoclonal
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.